Since April 2020, BRCA1/2 genetic testing has been covered by the national health insurance system in Japan for the diagnosis of hereditary breast and ovarian cancer (HBOC) in patients with breast cancer who meet specific criteria and in all with ovarian cancer [3]. The gene discussed is BRCA1; the disease is ovarian carcinoma.